ProActiv, Clinique, Other Acne Treatments Found to Contain Cancer-Causing Benzene Chemicals: Report
Laboratory testing found that certain acne treatments can generate levels of benzene 800 times higher than federal regulations allow.
Laboratory testing found that certain acne treatments can generate levels of benzene 800 times higher than federal regulations allow.
Second time in the last month GlaxoSmithKline has reached a Zantac settlement agreement just before a case was set to go before a jury, privately resolving claims that the recalled heartburn drug caused cancer
Although GlaxoSmithKline has agreed to several Zantac settlements payouts in recent months, the drug maker indicates that it plans to continue defending against cancer lawsuits being pursued by former users of Zantac.
GlaxoSmithKline, Boehringer Ingelheim, Pfizer and other drug makers face more than 70,000 Zantac cancer lawsuits in Delaware state court, after a U.S. District Judge dimissed all claims filed in the federal court system in 2022.
Settlement resolves four Zantac cancer lawsuits selected for bellwether trials in California, the first of which was expected to go before a jury begin in November.
Guidance comes after a number of massive drug recalls issued in recent years due to nitrosamine contamination, which could increase cancer risks.
Trial will be the first of tens of thousands of Zantac lawsuits filed in state courts nationwide to go before a jury, involving claims the recalled heartburn drug caused cancer.
The California Zantac lawsuit settlement terms are confidential, and GlaxoSmithKline claims it will continue to defend against other claims over the recalled heartburn medication.
The Defense Department is reportedly seeking Valisure's help in ensuring generic drugs, often manufactured overseas and away from FDA influence, given to military service members are safe and effective
The ruling means some California Zantac lawsuits are likely to go to before juries in the coming months, while appeals move forward over a controversial decision in the federal court system to exclude all plaintiffs' expert testimony.